Does advancing age weaken varicella-zoster-specific cell-mediated immunity and raise shingles and post-herpetic neuralgia risk?

Advancing age is strongly associated with weaker VZV-specific cellular immune control, helping explain why both shingles and its most consequential pain complication become more common in later life.

Clinical evidence

• Age-stratified cohorts show declining VZV-specific IFN-γ ELISpot responses: among healthy adults aged 40–80, responses correlated inversely with age (r = −0.356; p = 0.001), falling from a median 128 to 55.5 SFU/10⁶ PBMCs from the 40s to the 70s. Older-adult studies estimate approximately 3.9% annual decline.
• In community-dwelling adults aged ≥50, stronger baseline VZV-specific cell-mediated immunity was associated with lower subsequent shingles incidence; humoral immunity did not show the same association.
• For PHN, a prospective study of 70 zoster patients found that lower acute VZV-specific cellular responses predicted later PHN (adjusted OR 13.8; p = .04). Age itself is also an independent PHN predictor (adjusted OR 1.70 per decade at ages 50–79).

Mechanistic and clinical context

• VZV-specific CD4 T-cell/IFN-γ responses help suppress latent viral reactivation. Immunosenescence, including fewer responsive VZV-specific T cells and senescent/exhausted features, plausibly weakens this control; ex-vivo PD-1 blockade increasing proliferation suggests inhibitory pathways may contribute.
• Reduced immune control may promote PHN through more severe or prolonged acute zoster. Severe acute pain and rash predict PHN (summary rate ratios 2.23 and 2.63, respectively).

Prevention implications

• In 38,546 adults aged ≥60, live zoster vaccination reduced shingles by 51.3% and PHN by 66.5%, consistent with clinically meaningful restoration or augmentation of protective VZV immunity.

Bottom line

• For an 83-year-old man, age-related waning of VZV-specific cellular immunity is a well-supported contributor to elevated shingles risk and a plausible, prospectively supported contributor to PHN risk, especially when acute zoster is severe.